Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01593254
Title	Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)
Acronym	DASCERN
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Bristol-Myers Squibb
Indications	chronic myeloid leukemia
Therapies	Imatinib Dasatinib
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| ITA \| HUN \| FRA \| ESP \| CZE \| CAN \| BRA \| BEL \| AUT \| ARG